Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer

Onkologie

Volumn 33, Issue 6, 2010, Pages 324-330

  Lim, Myong Cheol ^a   Song, Yong Jung ^a   Seo, Sang Soo ^a   Yoo, Chong Woo ^a   Kang, Sokbom ^a   Park, Sang Yoon ^a  

^a National Cancer Center   (South Korea)

Author keywords

Cancer stem cell; Chemotherapy; Ovarian cancer

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; PACLITAXEL; PLATINUM; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CARCINOGENICITY; CELL RENEWAL; CYTOREDUCTIVE SURGERY; GENE MUTATION; HUMAN; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; REVIEW; SCAR; TREATMENT OUTCOME; TUMOR REGRESSION; ADJUVANT THERAPY; AGED; DRUG EFFECTS; FEMALE; MULTIMODALITY CANCER THERAPY; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 77953243271     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313823     Document Type: Review

References (57)

1. Lim MC, Lee DO, Kang S, Seo SS, Lee BY, Park SY: Clinical manifestations in patients with ovarian clear cell carcinoma with or without co-existing endometriosis. Gynecol Endocrinol 2009:1-6.
2. Huober J, Meyer A, Wagner U, Wallwiener D: The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. J Cancer Res Clin Oncol 2002;128:153-160.
3. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-1259.
4. Bristow RE, Puri I, Chi DS: Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009;112:265-274.
5. Bae J, Lim MC, Choi JH, Song YJ, Lee KS, Kang S, Seo SS, Park SY: Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. J Gynecol Oncol 2009;20: 101-106.
6. Lim MC, Bae J, Park SY: In reply: Different role of secondary cytoreductive surgery by surgeon's experience and hospital facility. J Gynecol Oncol 2009;20:199.
7. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-634.
8. Bristow RE, Eisenhauer EL, Santillan A, Chi DS: Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007;104:480-490.
9. Lim MC, Kang S, Choi J, Song YJ, Park S, Seo SS, Park SY: Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study. Ann Surg Oncol 2009;16:993-1000.
10. Lim MC, Kang S, Lee KS, Han SS, Park SJ, Seo SS, Park SY: The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecol Oncol 2009;112:28-34.
11. Lim MC, Lee HS, Jung DC, Choi JY, Seo SS, Park SY: Pathological diagnosis and cytoreduction of cardiophrenic lymph node and pleural metastasis in ovarian cancer patients using video-assisted thoracic surgery. Ann Surg Oncol 2009;16:1990-1996.
12. Vergote I, Trope CG, Amant F, Kristensen GB, Sardi JE, Ehlen T, Johnson N, Verheijen RHM, van der Burg AJ, Lacave AJ, Benedetti Panici P, Kenter GG, Casado A, Mendiola C, Coens C, Stuart G, Pecorelli S, Reed NS: EORTC-GCG/ NCIC-CTG randomized trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIc or IV ovarian, fallopian tube and peritoneal cancer. 12th Biennial Meeting International Gynecologic Cancer Society - IGCS, 2008
13. Baekelandt M: The potential role of neoadjuvant chemotherapy in advanced ovarian cancer. Int J Gynecol Cancer 2003;13(suppl 2):163-168.
14. Cancer Stem Cell and Stem Cell. The 10th Korean Cell Line Research Workshop, 2007.
15. Bunting KD: ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 2002;20:11-20.
16. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer 2008;18:506-514.
17. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP: The ABC transporter BCRP1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7: 1028-1034.
18. Li L, Xie T: Stem cell niche: structure and function. Annu Rev Cell Dev Biol 2005;21:605-631.
19. Donovan PJ, Gearhart J: The end of the beginning for pluripotent stem cells. Nature 2001;414:92-97.
20. Bukovsky A, Caudle MR, Svetlikova M, Upadhyaya NB: Origin of germ cells and formation of new primary follicles in adult human ovaries. Reprod Biol Endocrinol 2004;2:20.
21. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-3988. (Pubitemid 36418143)
22. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3: 730-737.
23. Al-Hajj M, Clarke MF: Self-renewal and solid tumor stem cells. Oncogene 2004;23:7274-7282.
24. Kondo T, Setoguchi T, Taga T: Persistence of a small subpopulation of cancer stem-like cells in the c6 glioma cell line. Proc Natl Acad Sci U S A 2004; 101:781-786.
25. Seigel GM, Campbell LM, Narayan M, Gonzalez- Fernandez F: Cancer stem cell characteristics in retinoblastoma. Mol Vis 2005;11:729-737.
26. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, Andreeff M, Goodell MA: A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001;98: 1166-1173.
27. Spillane JB, Henderson MA: Cancer stem cells: a review. ANZ J Surg 2007;77:464-468.
28. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (life): a randomised trial against atenolol. Lancet 2002;359:995-1003. (Pubitemid 34286536)
29. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL: Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 2004;428:145-150.
30. Kerr JB, Duckett R, Myers M, Britt KL, Mladenovska T, Findlay JK: Quantification of healthy follicles in the neonatal and adult mouse ovary: Evidence for maintenance of primordial follicle supply. Reproduction 2006;132:95-109.
31. Ness RB, Cottreau C: Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999;91:1459-1467.
32. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC: Current management strategies for ovarian cancer. Mayo Clin Proc 2007;82:751-770.
33. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
34. Hombach-Klonisch S, Paranjothy T, Wiechec E, Pocar P, Mustafa T, Seifert A, Zahl C, Gerlach KL, Biermann K, Steger K, Hoang-Vu C, Schulze-Osthoff K, Los M: Cancer stem cells as targets for cancer therapy: Selected cancers as examples. Arch Immunol Ther Exp (Warsz) 2008;56:165-180.
35. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E: Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007;131:1109-1123.
36. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK: Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci U.S.A 2006;103:11154-11159.
37. Tang C, Ang BT, Pervaiz S: Cancer stem cell: target for anti-cancer therapy. FASEB J 2007;21: 3777-3785.
38. Zhan Y, Fujino A, MacLaughlin DT, Manganaro TF, Szotek PP, Arango NA, Teixeira J, Donahoe PK: Mullerian inhibiting substance regulates its receptor/ SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Mullerian duct regression. Development 2006;133: 2359-2369.
39. Park SY: Neoadjuvant chemotherapy in advanced ovarian cancer. The 24th Annual Meeting of the Korean Society of Gynecologic Oncology and Colposcopy, 2009.
40. Smith JP, Rutledge F: Chemotherapy in the treatment of cancer of the ovary. Am J Obstet Gynecol 1970;107:691-703.
41. Donadio M, Bonardi G, Iberti V, Bertetto O, Carnino F, Iskra L, Mossetti C, Calciati A: The role of induction chemotherapy in inoperable ovarian cancer. Tumori 1989;75:609-614.
42. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, Pachyn D, Ulm K, Graeff H: Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in international federation of gynecology and obstetrics stage IIIc ovarian carcinoma. Cancer 2001;92:2585-2591.
43. Le T, Alshaikh G, Hopkins L, Faught W, Fung MF: Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Ann Surg Oncol 2006;13:1711-1716. (Pubitemid 44951481)
44. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP: Neoadjuvant chemotherapy for advanced ovarian cancer: Long-term survival. Gynecol Oncol 1999;72:93-99.
45. Du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U: 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC), 2004. Ann Oncol 2005;16(suppl 8): viii7-viii12.
46. Song YJ, Lim MC, Kang S, Seo SS, Park JW, Choi HS, Park SY: Total colectomy as part of primary cytoreductive surgery in advanced Mullerian cancer. Gynecol Oncol 2009;114:183-187.
47. Bristow RE, Peiretti M, Zanagnolo V, Salani R, Giuntoli RL, 2nd, Maggioni A: Transverse colectomy in ovarian cancer surgical cytoreduction: operative technique and clinical outcome. Gynecol Oncol 2008;109:364-369.
48. Yildirim Y, Sanci M: The feasibility and morbidity of distal pancreatectomy in extensive cytoreductive surgery for advanced epithelial ovarian cancer. Arch Gynecol Obstet 2005;272:31-34.
49. Chi DS, Diaz JP, Jarnagin WR: Distal partial gastrectomy and gastrojejunal anastomosis for recurrent ovarian cancer. Gynecol Oncol 2007;104: 33-36.
50. Eitan R, Levine DA, Abu-Rustum N, Sonoda Y, Huh JN, Franklin CC, Stevens TA, Barakat RR, Chi DS: The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. Cancer 2005;103:1397-1401.
51. Chan YM, Ng TY, Ngan HY, Wong LC: Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: A prospective longitudinal study. Gynecol Oncol 2003;88:9-16.
52. Morice P, Brehier-Ollive D, Rey A, Atallah D, Lhomme C, Pautier P, Pomel C, Camatte S, Duvillard P, Castaigne D: Results of interval debulking surgery in advanced stage ovarian cancer: An exposed- non-exposed study. Ann Oncol 2003;14:74-77. (Pubitemid 36150262)
53. Le T, Faught W, Hopkins L, Fung Kee Fung M: Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer. Int J Gynecol Cancer 2005; 15:770-775.
54. Everett EN, French AE, Stone RL, Pastore LM, Jazaeri AA, Andersen WA, Taylor PT, Jr.: Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. Am J Obstet Gynecol 2006;195:568-574; discussion 574-1566
55. Lee SJ, Kim BG, Lee JW, Park CS, Lee JH, Bae DS: Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynaecol Res 2006;32:99-106.
56. Steed H, Oza AM, Murphy J, Laframboise S, Lockwood G, DE Petrillo D, Sturgeon J, Rosen B: A retrospective analysis of neoadjuvant platinumbased chemotherapy versus up-front surgery in advanced ovarian cancer. Int J Gynecol Cancer 2006; 16(suppl 1):47-53.
57. Bilici A, Salepci T, Dane F, Gumus M, Ustaalioglu BB, Seker M, Salman T, Turan C, Unal O, Yaylaci M: Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: A single centre experience. Arch Gynecol Obstet 2009 Dec 25. [Epub ahead of print].